Insmed (INSM) Gains from Investment Securities (2021 - 2026)

Insmed has reported Gains from Investment Securities for 6 years, with the latest figure at -$99.8 million in Q2 2026.

• On a quarterly basis, Gains from Investment Securities fell 269.08% year-over-year to -$99.8 million in Q2 2026; TTM through Jun 2026 was $28.0 million, a 63.76% decrease from a year earlier, with the FY2025 full-year figure at $252.0 million, up 174.86% from the prior year.
• Gains from Investment Securities was -$99.8 million for Q2 2026 at Insmed, down from -$47.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $104.7 million in Q3 2025, with the low at -$99.8 million in Q2 2026.
• Average Gains from Investment Securities over 5 years is $11.4 million, with a median of $7.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Gains from Investment Securities jumped 972.22% in 2023, then plunged 356.62% in 2026.
• Over 5 years, Gains from Investment Securities stood at -$1.8 million in 2022, then surged by 972.22% to $15.7 million in 2023, then plunged by 194.27% to -$14.8 million in 2024, then soared by 573.24% to $70.0 million in 2025, then plunged by 242.43% to -$99.8 million in 2026.
• The last three Gains from Investment Securities figures came in at -$99.8 million (Q2 2026), -$47.0 million (Q1 2026), and $70.0 million (Q4 2025), per Business Quant data.